| This article has been cited by |
| 1 | Determination of urinary aldosterone using a plasma aldosterone 2D ID LC–MS/MS method | |
| Yasin Bekkach,Annemieke C Heijboer,Erik Endert,Mariëtte T Ackermans |
| Bioanalysis.2016;8(17)1765 |
| [DOI] |
|
| 2 | Developing an ultra-performance liquid chromatography-tandem mass spectrometry for detecting aldosterone in human plasma | |
| Wenbin Lin,Zhenrong Yao,Yuzhe Li,Zhihao Liao,Jiahao Xiao,Yonghong Chen,Pinning Feng,Wenjia Gan |
| Journal of Clinical Laboratory Analysis.2021;35(11)1765 |
| [DOI] |
|
| 3 | Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography–tandem mass spectrometry determinations of plasma aldosterone concentration | |
| Stephanie Baron,Laurence Amar,Anne-Laure Faucon,Anne Blanchard,Laurence Baffalie,Catherine Faucard,Simon Travers,Jean-Yves Pagny,Michel Azizi,Pascal Houillier |
| Journal of Hypertension.2018;36(7)1592 |
| [DOI] |
|
| 4 | Clinical Evaluation of Assays for Plasma Renin Activity and Aldosterone Measurement by Liquid Chromatography–Tandem Mass Spectrometry | |
| Stephen M Gibbons,Helen P Field,April Fairhurst,Anne Fleming,Clive Ford,Emma L Williams,Sophie C Barnes,Julian H Barth |
| The Journal of Applied Laboratory Medicine.2021;6(3)668 |
| [DOI] |
|
| 5 | Statins: Adverse reactions, oxidative stress and metabolic interactions | |
| Aimei Liu,Qinghua Wu,Jingchao Guo,Irma Ares,José-Luis Rodríguez,María-Rosa Martínez-Larrañaga,Zonghui Yuan,Arturo Anadón,Xu Wang,María-Aránzazu Martínez |
| Pharmacology & Therapeutics.2019;195(3)54 |
| [DOI] |
|
